Partnering with expert key opinion leaders
Innovation is one of our core values, and collaboration is key to advancing treatments for neurological diseases. Working with partners in academia, business and charitable organisations, we help further the international scientific and regulatory agenda and provide access to our platform and advanced data analysis for innovative research.
For a full list of partners and collaborators, see our News section
EPAD & AMYPAD are international consortia where IXICO’s expertise and TrialTracker™ digital platform is being used to standardise the collection of MRI and PET imaging data from 6000 people recruited from clinical centres all over Europe.
Research increasingly focuses on ways to prevent the onset of Alzheimer’s disease in the first phases. The EPAD project is pioneering a novel, more flexible approach to clinical trials of drugs designed to prevent Alzheimer’s disease.
AMYPAD aims to improve the understanding, diagnosis and management of Alzheimer’s disease through the utilisation of ß-amyloid PET imaging.
In both EPAD and AMYPAD projects:
- IXICO data analysis algorithms quantitatively analyse brain scans and maximise the information extracted and increase chances of detecting therapy-induced changes in clinical trials
- IXICO artificial intelligence data analytics will be used to combine imaging with other data captured from patients, to predict the rate of disease progression in individual patients and identify those people who could benefit from enrolment in clinical trials aimed at preventing Alzheimer’s disease
Coalition Against Major Diseases (CAMD) is a public-private partnership aimed at creating new tools and methods that can be applied to increase the efficiency of the development process of new treatments for Alzheimer’s disease and related neurodegenerative disorders.
IXICO’s data management and regulatory scientists are enabling the following CAMD initiatives:
- The qualification of low baseline hippocampal volume for use in Alzheimer’s disease clinical trials for selecting subjects as having a high probability of being in the prodromal stage of the disease
- Progress the regulatory landscape for the use of Digital Biomarker Measures as endpoints in clinical trials to support regulatory approval of new medicines to treat people with Mild Cognitive Impairment
To speak to one of our experts and find out more